Výsledky vyhledávání - "Onno J H M, Verhagen"

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model

Autor: Heng Sheng, Sow, Hreinn, Benonisson, Cor, Breukel, Remco, Visser, Onno J H M, Verhagen, Arthur E H, Bentlage, Conny, Brouwers, Jill W C, Claassens, Margot M, Linssen, Marcel, Camps, Thorbald, van Hall, Ferry, Ossendorp, Marieke F, Fransen, Gestur, Vidarsson, J Sjef, Verbeek

Publikováno v: International journal of cancer. 144(2)

Immunomodulatory antibodies blocking interactions of coinhibitory receptors to their ligands such as CTLA-4, PD1 and PD-L1 on immune cells have shown impressive therapeutic efficacy in clinical studies. The therapeutic effect of these antibodies is m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6fa9445e93b66321779ced19055756c7
https://pubmed.ncbi.nlm.nih.gov/30259976

Zobrazit plný text záznamu

Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D

Autor: Rick, Kapur, Luciana, Della Valle, Onno J H M, Verhagen, Agnes, Hipgrave Ederveen, Peter, Ligthart, Masja, de Haas, Belinda, Kumpel, Manfred, Wuhrer, C Ellen, van der Schoot, Gestur, Vidarsson

Publikováno v: Transfusion. 55(3)

RhIG is obtained from hyperimmunized healthy anti-D donors (HIDs) boosted with D+ red blood cells (RBCs). One hypothesis for its mechanism of action is fast clearance of opsonized D+ RBCs through Fcγ receptor (FcγR)III. Levels of immunoglobulin (Ig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::803a848fe0f1d1a9c7a66c27a47b94d3
https://pubmed.ncbi.nlm.nih.gov/25234110

Zobrazit plný text záznamu

Detection of circulating breast tumor cells by differential expression of marker genes

Autor: Astrid J, Bosma, Britta, Weigelt, A Caro, Lambrechts, Onno J H M, Verhagen, Roelof, Pruntel, Augustinus A M, Hart, Sjoerd, Rodenhuis, Laura J, van 't Veer

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 8(6)

We undertook a systematic approach to identify breast cancer (BC) marker genes with molecular assays and evaluated these marker genes for the detection of minimal residual disease in peripheral blood mononuclear cells (PBMCs).We used serial analysis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c0b577326748318919226d50e983c8aa
https://pubmed.ncbi.nlm.nih.gov/12060630

Zobrazit plný text záznamu

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse

Autor: Onno J. H. M. Verhagen, Henk van den Berg, Valerie de Haas, C. Ellen van der Schoot, Willemÿn B. Breunis

Publikováno v: Blood. 96:1619-1620

We read with interest the report of Panzer-Grumayer et al[1][1] in which the authors showed that evaluation of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) by semiquantitative molecular methods on day 15 of induction

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2752beb79f126c4c5069e3bea8b10434
https://doi.org/10.1182/blood.v96.4.1619

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání